Investor Ideas #Potcasts; #Cannabis News and #Stocks on the Move
(NASDAQ: $GWPH) (CSE: $CURA.C) (CSE: $OH.C) (NASDAQ: $OGI) (CSE: $CL.C)
Delta, Kelowna, BC –July
26, 2019 (Investorideas.com Newswire) www.Investorideas.com, a global news
source covering leading sectors including marijuana and hemp stocks and its
potcast site, www.potcasts.ca release today’s edition of Investorideas.com potcastsCM -
cannabis news and stocks to watch plus insight from thought leaders and
experts.
Listen to the podcast:
Read this in full
at https://www.investorideas.com/news/2019/cannabis-potcasts/07261GWPH-CURA-OH-OGI-CL.asp
Today’s podcast overview/transcript:
Good afternoon
and welcome to another episode of Investorideas.com “Potcast” featuring
cannabis news, stocks to watch as well as insights from thought leaders and
experts.
In
today’s podcast we look at a few early announcements.
But first, The
Cannabis
Council of Canada responded to the draft regulation by the Quebec
government to ban the sale of certain edible cannabis products and cannabis
extracts:
"Yesterday's decision by the Quebec
government to issue draft regulation with respect to edible cannabis products
and cannabis extracts is extremely disappointing. If implemented, the efforts
of the legal cannabis industry to replace the illicit market and keep cannabis
out of the hands of minors will be severely hindered," said Megan McCrae,
Board Chair, Cannabis Council of Canada.
The proposed regulation would ban the sale
of treat, confectionery, dessert, and chocolate edible products and all
products believed by the Quebec government to have a direct appeal to minors.
In addition, a cannabis extract may not contain any additives or other
substances intended to modify the odor, taste or color. In addition, it
proposes to place a maximum cap of 30% THC on non-edible products, which will
have the effect of curtailing other products – such as vape pens – from
entering the Quebec market. The proposed regulation would also ban cannabis
topicals.
The Cannabis Council of Canada strongly
support the ethos of the proposed regulations, but its current form inhibits
the legal, regulated cannabis industry from producing and selling a diversity
of products in a controlled, responsible manner to Quebec cannabis consumers,
and instead supports the illicit market for these products. The unregulated
production and distribution of cannabis enriches organized crime and puts youth
at risk. According to public opinion research conducted on behalf of the
Cannabis Council of Canada, 64% of Quebecers support the legalization of
cannabis, as well as safe, regulated access to cannabis products.
The Cannabis Council of Canada is the
national voice for Canada's licensed cannabis producers which advocate for
world-leading federal regulation and the safe, responsible production, access
and use of recreational and medical cannabis products.
GW Pharmaceuticals
plc (NASDAQ: GWPH) today announced that the European Medicines Agency’s (EMA)
Committee for Medicinal Products for Human Use (CHMP) has adopted a positive
opinion recommending marketing authorisation of EPIDYOLEX™ (cannabidiol oral
solution) for use as adjunctive therapy of seizures associated with Lennox‑Gastaut syndrome (LGS) or Dravet syndrome,
in conjunction with clobazam, for patients 2 years of age and older. The
European Commission (EC) is expected to make a final decision on the marketing
authorisation application (MAA) in approximately two months.
“Today’s
positive CHMP opinion for EPIDYOLEX™ marks a major milestone for patients, and
their families, battling to control two of the most severe and life-threatening
forms of childhood onset epilepsy. Cannabidiol oral solution is the first in a
new class of epilepsy medicines and the first plant-derived cannabis-based
medicine to be submitted for European regulatory review, representing a
historic breakthrough,” said Justin Gover, GW’s Chief Executive Officer. “We
are excited by the potential to bring patients and physicians a rigorously
tested and evaluated cannabis-based medicine with a documented safety and
efficacy profile, manufactured to the highest standards and approved by a
medicines regulator.”
“This
is a significant milestone for patients with LGS and Dravet syndrome as there
remains a severe unmet medical need for these rare, lifelong forms of
epilepsy,” said Professor Martin Brodie, President, International Bureau for
Epilepsy. “Today’s positive opinion brings hope to both patients and their
families of a treatment option which has the potential to better control
seizures and notably improve quality of life.”
“In
my clinic, I often see patients with these highly treatment-resistant
epilepsies who have tried and failed existing therapies. These patients and
their families face a long and challenging road and very few achieve adequate
seizure control,” said Dr Antonio Gil-Nagel Rein, Director of the Epilepsy
Programme, Ruber International Hospital, Madrid. “Based on numerous clinical
trials and the scrutiny of the European medicines regulator, this medicine has
the potential to make a real difference to the lives of many patients.”
The
CHMP’s positive opinion is based on results from four randomised, controlled
Phase 3 trials. These studies incorporate data from more than 714 patients with
either LGS or Dravet syndrome, two forms of epilepsy with high morbidity and mortality
rates, which place a significant burden on families and caregivers. Many
patients with LGS or Dravet syndrome have multiple seizures per day, which puts
them at ongoing risk of falls and injury. Despite current anti-epileptic drug
treatment, both of these severe forms of epilepsy remain highly
treatment-resistant.
Curaleaf Holdings,
Inc. (CSE: CURA) (OTCQX: CURLF) responded yesterday to a letter from the U.S. Food and Drug
Administration
("FDA") informing FDA that the Company has addressed the issues that
were raised in the letter regarding its CBD product marketing.
Upon
receiving the letter, Curaleaf Hemp, the Company's hemp-based CBD product line,
immediately began an extensive review of its website and social media platforms
to remove all statements that FDA identified as non-compliant. This includes
removing the Curaleaf Hemp blog, and the third-party links in it, and removing
any statements and social media posts to which FDA had taken exception.
Additionally, Curaleaf Hemp advised FDA that a number of the products mentioned
in the FDA letter had previously been discontinued. Curaleaf Hemp will continue
to work diligently to ensure that the information it provides to consumers on
its website and social media platforms is fully compliant with FDA
requirements.
"Our
industry needs, wants and appreciates the work the FDA is doing to ensure there
is regulation and compliance in the CBD marketplace," said Joseph Lusardi,
CEO of Curaleaf.
"We
care deeply about our customers and making a difference in our industry.
Curaleaf is committed to being an ethical and responsible company and working
with the FDA to be a leader in our industry, setting the standards and
guidelines to best service our customers and the communities we serve."
Organigram Holdings
Inc. (NASDAQ: OGI) (TSX-V: OGI) announced that it has entered into an advance
payment and purchase agreement with 703454 N.B. Inc. (1812 Hemp) under which
the Company will pre-fund hemp purchases to receive access to as much as 60,000
kilograms of dried hemp flower to be harvested in calendar 2019 for extraction
into CBD isolate.
Organigram
is already a party to a purchase agreement entered into in January 2019 with
1812 Hemp, in which Organigram was granted a right of first refusal on 1812
Hemp’s production of certain hemp cultivars.
“Access
to a large, consistent volume of CBD-producing hemp has become increasingly
important as Canadians express their demand for CBD-rich products for use in
both recreational and medical capacities,” said Greg Engel, CEO, Organigram.
“We’ve heard the call for CBD in the market and this agreement positions
Organigram to meet that demand.”
CannaRoyalty Corp.
d/b/a Origin House (CSE: OH) (OTCQX: ORHOF) announced today that it has divested its 5.1% equity
interest in Alternative Medical Enterprises LLC for total consideration of US$6
Million. As Cresco Labs Inc. is
prohibited under state law from acquiring additional positions in the Florida
market, this divestment was a pre-closing condition to the Company's previously
announced plan of arrangement pursuant to which Cresco has agreed to acquire
all of the issued and outstanding shares of Origin House.
"With
one of the final conditions to closing the Arrangement with Cresco now
complete, we look forward to proceeding to drive value for shareholders as a
combined company, upon the expiration of the anti-trust waiting period,"
commented Marc Lustig, Chairman and CEO of Origin House. "The sale of the
remaining AltMed interest marks a significant milestone in the continued
process whereby Origin House has monetized non-core holdings resulting in both
substantial returns for shareholders and additional cash that has fueled the
Company's growth."
The
Company has received approximately US$3 million on close, with the remaining
portion of approximately US$3 million, paid to Origin House in periodic
installments, ending January 2020. Mr. Lustig has agreed with one of the
purchasers that acquired 4.9% of the 5.1% Interest, Zola Global Investors Ltd.,
to personally repurchase a portion of their interest in AltMed under certain
conditions. Zola is an operationally focused family office with deep expertise
in investing across the legal cannabis sector, providing a source of capital
for corporations divesting assets as part of their merger requirements.
Cresco Labs, Inc. (CSE: CL) (OTCQX: CRLBF) announced that it has obtained eligibility with The
Depository Trust Company (DTC) for its common shares listed on the OTCQX.
“Our
shareholders will now be able to electronically transfer shares between
brokerages in the U.S.,” said Charles Bachtell, Co-founder and CEO of Cresco
Labs. “DTC will allow for a more convenient trading experience for current and
future shareholders, something we hope will have a positive impact on the
liquidity and demand of our stock.”
Investor ideas reminds all listeners to read our disclaimers and
disclosures on the
Investorideas.com website and this podcast is not an endorsement
to buy products or services or securities. Investors are reminded all
investment involves risk and possible loss of investment
Subscribe to the new cannabis podcast series:
Investorideas.com podcasts are also available
on iTunes, Spotify, Google Play Music,
Stitcher, Spreaker, YouTube via
Spreaker, iHeartradio and Tunein.
Potcasts is now a certified word mark Trademark
on the blockchain through Cognate, Inc. CM Certification-Registration Number:
10468217708
About Investorideas.com - News that Inspires Big Investing Ideas
Investorideas.com is a recognized news
source publishing third party news and press releases plus we create original
financial content. Learn about investing in stocks and sector trends
from Investorideas.com with our news alerts , articles , podcasts and videos talking about cannabis, crypto,
technology including AI and IoT ,
mining ,sports biotech, water, renewable energy and more . Investorideas.com
original branded content includes the daily Crypto Corner and Podcast, Play
by Play sports and stock news column, Investor Ideas #Potcasts #Cannabis News
and Stocks on the Move podcast and column,
Cleantech and Climate Change Podcast and
the AI
Eye Podcast and column covering developments in
AI.
Disclaimer/Disclosure: Investorideas.com is a
digital publisher of third party sourced news, articles and equity research as
well as creates original content, including video, interviews and articles.
Original content created by investorideas is protected by copyright laws other
than syndication rights. Our site does not make recommendations for purchases
or sale of stocks, services or products. Nothing on our sites should be
construed as an offer or solicitation to buy or sell products or securities.
All investing involves risk and possible losses. This site is currently compensated
for news publication and distribution, social media and marketing, content
creation and more. Disclosure is posted for each compensated news release,
content published /created if required but otherwise the news was not
compensated for and was published for the sole interest of our readers and
followers. Contact management and IR of each company directly regarding
specific questions.
More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn
more about publishing your news release and our other news services on the
Investorideas.com newswire https://www.investorideas.com/News-Upload/ and
tickertagstocknews.com
Global investors must adhere to regulations of each
country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp
Investor Ideas does not condone the use of cannabis except where
permissible by law. Our site does not possess, distribute, or sell cannabis
products.
Follow us on Social Media
Contact Investorideas.com
800-665-0411
No comments:
Post a Comment